Several studies have consistently shown that HIV-positive women present higher risk of cervical intraepithelial neoplasia (CIN) persistence or recurrence after standard therapy.9,11–16 These features have led some clinicians to reevaluate the efficacy of traditional therapy for CIN grades 2 or 3 (CIN 2-3) among HIV-infected women.17–22 However, prognostic factors such as CD4 count, positive margins from excisional procedures and use of HAART have not been consistently correlated with this event.12,15,16,23–25. This evidence concerns the gene CD4 and cervical squamous intraepithelial neoplasia.